Sotera Health posts Q3 2026 earnings beat and reaffirms 2026 outlook amid European demand softness
Sotera Health reported third‑quarter 2026 adjusted earnings of $0.29 per share on revenue of $324.9 million, beating expectations. Revenue grew 4.4% on a constant‑currency basis and adjusted EBITDA rose 4% to $171 million, with the margin expanding to 52.5%. Management highlighted softening medical‑device demand in Europe, flat Sterigenics revenue expected for Q4, and reaffirmed its 2026 revenue and adjusted EBITDA growth targets.
Why it matters
The company’s reaffirmation of 2026 revenue growth of 5.25%‑6.75% and adjusted EBITDA growth of 5.75%‑7.25% signals continued upside potential for investors. Net leverage improved to 2.9x, within the 2.0‑3.0x target range, supporting a recent Moody’s credit rating upgrade.
Key facts
- 1Adjusted earnings per share were $0.29. investing.com
- 2Revenue was $324.9 million. investing.com
- 3Revenue grew 4.4% on a constant‑currency basis. finance.yahoo.com
- 4Adjusted EBITDA was $171 million, up 4% on a constant‑currency basis. finance.yahoo.com
- 5Adjusted EBITDA margin expanded to 52.5%. investing.com
- 6Net leverage ratio improved to 2.9x. investing.com
Summary written by AlphAI AI Desk from 6 of 6 sources. Not investment advice. Figures are as stated by the linked sources.